The Effects of Macular Photocoagulation on Visual Field
Journal of Ophthalmic and Optometric Sciences,
Vol. 5 No. 4 (2021),
1 May 2023
,
Page 47-52
https://doi.org/10.22037/joos.v5i4.38515
Abstract
Purpose: To evaluate visual field and nerve fiber layer thickness changes after Macular photocoagulation for treatment of diabetic macular edema.
Setting: Rassoul Akram Hospital, Tehran, Iran.
Material and method: Twenty six eyes with history of diabetes and clinically significant macular edema candidate for Macular photocoagulation were included in this prospective interventional case series. All patients underwent 10-2 and 24-2 Humphrey Visual Field Test with Swedish Interactive Thresholding Algorithm (SITA) standard strategy and also optic nerve and macular optical coherence tomography (OCT), before and 6 months after macular laser photocoagulation. Then visual field, peripapillary and macular nerve fiber layer thickness of each eye were compared before and after photocoagulation.
Results: The mean age of patients was 57.60 ± 8.99 (range 33-73) years. There was no statistically significant change after photocoagulation compared to before the procedure regarding the mean deviation, pattern standard deviation and foveal threshold in visual field 10-2 and 24-2 tests except for pattern standard deviation in 10-2 test.
Conclusion: Based on our results it seems that visual field is not affected by macular laser photocoagulation.
- Glaucoma
- Macular Photocoagulation
- Visual Field
How to Cite
References
Javitt JC, Aiello LP, Chiang Y, Ferris III FL, Canner JK, Greenfield S. Preventive eye care in people with diabetes is cost-saving to the federal government: implications for health-care reform. Diabetes care. 1994;17(8):909-17.
Ferris III FL, Patz A. Macular edema. A complication of diabetic retinopathy. Survey of ophthalmology. 1984;28:452-61.
Antcliff R, Marshall J, editors. The pathogenesis of edema in diabetic maculopathy. Seminars in ophthalmology; 1999: Taylor & Francis.
Group ETDRSR. Early treatment diabetic retinopathy study report number 1; Photocoagulation for diabetic macular edema. Arch Ophthalmol. 1985;103:1796-806.
Group ETDRSR. Early photocoagulation for diabetic retinopathy: ETDRS report number 9. Ophthalmology. 1991;98(5):766-85.
Iijima H. Humphrey perimetry and retinal diseases. Nippon Ganka Gakkai Zasshi. 2016;120(3):190-208; discussion 9.
Bengtsson B, Heijl A. SITA Fast, a new rapid perimetric threshold test. Description of methods and evaluation in patients with manifest and suspect glaucoma. Acta Ophthalmologica Scandinavica. 1998;76(4):431-7.
Katz J, Sommer A. Reliability indexes of automated perimetric tests. Archives of ophthalmology. 1988;106(9):1252-4.
Olk RJ. Modified grid argon (blue-green) laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1986;93(7):938-50.
Olk RJ. Argon green (514 nm) versus krypton red (647 nm) modified grid laser photocoagulation for diffuse diabetic macular edema. Ophthalmology. 1990;97(9):1101-13.
Striph GG, Hart Jr WM, Olk RJ. Modified grid laser photocoagulation for diabetic macular edema: the effect on the central visual field. Ophthalmology. 1988;95(12):1673-9.
Hudson C, Flanagan J, Turner G, Chen H, Young L, McLeod D. Influence of laser photocoagulation for clinically significant diabetic macular oedema (DMO) on short-wavelength and conventional automated perimetry. Diabetologia. 1998;41:1283-92.
Sims LM, Stoessel K, Thompson JT, Hirsch J. Assessment of visual-field changes before and after focal photocoagulation for clinically significant diabetic macular edema. Ophthalmologica. 1990;200(3):133-41.
Bressler NM, Varma R, Mitchell P, Suñer IJ, Dolan C, Ward J, et al. Effect of ranibizumab on the decision to drive and vision function relevant to driving in patients with diabetic macular edema: report from RESTORE, RIDE, and RISE trials. JAMA ophthalmology. 2016;134(2):160-6.
Schaumberg DA, Rose L, DeAngelis MM, Semba RD, Hageman GS, Chasman DI. Prospective study of common variants in CX3CR1 and risk of macular degeneration: pooled analysis from 5 long-term studies. JAMA ophthalmology. 2014;132(1):84-95.
Heier JS, Korobelnik J-F, Brown DM, Schmidt-Erfurth U, Do DV, Midena E, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies. Ophthalmology. 2016;123(11):2376-85.
- Abstract Viewed: 107 times
- pdf Downloaded: 70 times
